The DOI matches its Crossref record; 113 of the 115 references it cites were found in a registry or an index.
Metformin and Cancer Risk and Mortality: A Systematic Review and Meta-analysis Taking into Account Biases and Confounders
Open accessPublished version of a preprint
Abstract
Previous meta-analyses have shown that the antidiabetic agent metformin is associated with reduced cancer incidence and mortality. However, this effect has not been consistently demonstrated in animal models and recent epidemiologic studies. We performed a meta-analysis with a focus on confounders and biases, including body mass index (BMI), study type, and time-related biases. We identified 71 articles published between January 1, 1966, and May 31, 2013, through Pubmed, ISI Web of Science (Science Citation Index Expanded), Embase, and the Cochrane library that were related to metformin and cancer incidence or mortality. Study characteristics and outcomes were abstracted for each study that met inclusion criteria. We included estimates from 47 independent studies and 65,540 cancer cases in patients with diabetes. Overall cancer incidence was reduced by 31% [summary relative risk (SRR), 0.69; 95% confidence interval (CI), 0.52–0.90], although between-study heterogeneity was considerable (I2 = 88%). Cancer mortality was reduced by 34% (SRR, 0.66; 95% CI, 0.54–0.81; I2 = 21%). BMI-adjusted studies and studies without time-related biases also showed significant reduction in cancer incidence (SRR, 0.82; 95% CI, 0.70–0.96 with I2 = 76% and SRR, 0.90; 95% CI, 0.89–0.91 with I2 = 56%, respectively), albeit with lesser magnitude (18% and 10% reduction, respectively). However, studies of cancer mortality and individual organ sites did not consistently show significant reductions across all types of analyses. Although these associations may not be causal, our results show that metformin may reduce cancer incidence and mortality in patients with diabetes However, the reduction seems to be of modest magnitude and not affecting all populations equally. Clinical trials are needed to determine if these observations apply to nondiabetic populations and to specific organ sites. Cancer Prev Res; 7(9); 867–85. ©2014 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“long-term use of metformin in type 2 diabetes patients has been linked to a decline in tumor incidence and a reduced rate of cancer-related deaths.192–196”
From Drug repurposing for cancer therapy (2024) · cites this paper as [192]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“a more thorough analysis that included more data and accounted for heterogeneous comparators showed that overall cancer incidence was reduced by 31% and cancer mortality by 34% (Gandini et al., 2014).”
From Metformin as a tool to target aging (2016) · cites this paper as Gandini et al., 2014
In the citing paper
“Furthermore, retrospective clinical studies have found that metformin use is associated with improved cancer outcomes, reductions in cancer incidence, and decreased cancer mortality (Evans et al., 2005; Franciosi et al., 2013; Gandini et al., 2014; Lee et al., 2012; Noto et al., 2012).”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Gandini et al., 2014
In the citing paper
“Extensive support for a protective effect of metformin against cancer has been provided by numerous, but not all studies (237, 238).”
From A Critical Review of the Evidence That Metformin Is a Putative Anti-Aging Drug That Enhances Healthspan and Extends Lifespan (2021) · cites this paper as [237]
In the citing paper
“In a meta-analysis(255), metformin-treated diabetic patients had a 31% reduction in the incidence of cancer and a 34% reduction in cancer mortality after adjusting for body mass index(255).”
From Metformin, the Aspirin of the 21st Century: Its Role in Gestational Diabetes Mellitus, Prevention of Preeclampsia and Cancer, and the Promotion of Longevity (2017) · cites this paper as [255]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Metformin monotherapy for type 2 diabetes mellitus
Sáenz, A., Fernandez-Esteban, I., Mataix, A. L., Segura, M. A., Figuls, M. R. I., & Moher, D. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002966.pub3 · Cited by 310
RetractedPreferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040296 · Cited by 23,020
Meta-analysis of Observational Studies in Epidemiology<SUBTITLE>A Proposal for Reporting</SUBTITLE>
Stroup, D. F. (2000) · JAMA · doi:10.1001/jama.283.15.2008 · Cited by 20,623
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.005 · Cited by 19,575
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011 · cited 2×
“Furthermore, metformin is the drug of choice in obese patients with diabetes because it reduces weight (3, 100), so its use is associated with obesity.”
Backgroundvon Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., & Vandenbroucke, J. P. (2008) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2007.11.008 · Cited by 17,893
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-8-200710160-00010 · Cited by 17,796
Cited by
Sorted by citations
Items 401–457 of 457
Metformin: an old drug with potential therapeutic function in antitumorPreprint
Mu, W., Jiang, Y., & Qu, F. (2021) · doi:10.22541/au.163640852.26812577/v1
Hassan, S. S., Bedir, E. A., Hamza, A. E. M., Ahmed, A. M., Ibrahim, N. M., El‐Ghany, M. S. A., Sayed, N. N., Eimera, B. M., Salama, M. M., Mohamed, E. F., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4015275
Metformin Resistant MDA-MB-468 Cells Exhibit EMT-like Phenotype and Increased Migration CapacityPreprint
Köker, Ş. C., Yalçin, B., & Doğan, İ. (2021) · Research Square · doi:10.21203/rs.3.rs-382083/v2
Molecular Heterogeneity in Primary and Metastatic Prostate Tumor Tissue
Batista, J. L. (2015) · Defense Technical Information Center (DTIC) · doi:10.21236/ada621180
Metformin Inhibit Cell Proliferation and Secretion Function in NCI-H295R CellsPreprint
Li, C., Wang, F., Tong, A., Yan, Z., & Li, Y. (2020) · doi:10.21203/rs.3.rs-26937/v1
UJI SITOTOKSIK METFORMIN HIDROKLORIDA TERHADAP SEL KANKER PAYUDARA T47D
Rangkuti, I. Y. (2019) · Jurnal Kedokteran Syiah Kuala · doi:10.24815/jks.v19i3.10568
Lazzeroni, M., & Gandini, S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.65133-4 · Cited by 1
Self-citationCensi, A. D., Bonanni, B., & Cazzaniga, M. (2017) · Springer eBooks · doi:10.1007/978-3-319-48848-6_9
(2017) · Elsevier eBooks · doi:10.1016/b978-0-12-812896-1.00040-4
Aging in Stem Cells: Traditional Review
DURMAZ, C., & ŞEN, E. (2022) · Turkiye Klinikleri Journal of Health Sciences · doi:10.5336/healthsci.2021-84348
Cellular senescence during aging
von Zglinicki, T. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-823761-8.00017-3
Colorectal Cancer Chemoprevention
Howells, L. M., & Brown, K. S. (2015) · Springer eBooks · doi:10.1007/978-3-642-27841-9_7223-1
Hormonal Imbalance and Breast Cancer in Women
Manasa Mohan, A., & Thomas, S. (2022) · Acta Scientific Women s Health · doi:10.31080/aswh.2022.04.0444
Chang, M. S., Hartman, R. I., Xue, J., Giovannucci, E. L., Nan, H., & Yang, K. (2023) · doi:10.1158/1940-6207.c.6547417.v1
Brown, J. C., Zhang, S., Ligibel, J. A., Irwin, M. L., Jones, L. W., Campbell, N., Pollak, M., Sorrentino, A., Cartmel, B., Harrigan, M., et al. (2023) · doi:10.1158/1940-6207.c.6547643.v1
Sharrack, N., Knott, K. D., Gulsin, G. S., Kotecha, T., Brown, L., Yeo, J. L., Porcari, A., Adam, R. D., Thirunavukarasu, S., Chowdhary, A., et al. (2023) · medRxiv · doi:10.1101/2023.04.13.23288441
Qin, L., Fan, Q., & Wu, J. W. (2023) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1155/2023/5575513
Cancer risk in polycystic ovary syndrome patients: Common treatments and future perspectives
Shahrin, A., Mele, M. A., & Islam, M. K. (2023) · Journal of Multidisciplinary Sciences · doi:10.33888/jms.2023 · Cited by 1
Shiba, S., Kitayama, J., Harao, M., Saito, A., SAKURAGI, M., Lefor, A. K., & Sata, N. (2023) · Research Square · doi:10.21203/rs.3.rs-3271592/v1
Current Preclinical Applications of Pharmaco-Epigenetics in Cardiovascular Diseases
Papulino, C., Chianese, U., Scisciola, L., Ali, A. H., Barbieri, M., Paolisso, G., Altucci, L., & Benedetti, R. (2023) · Epigenetics and human health · doi:10.1007/978-3-031-42365-9_9
ADVANTAGES OF METFORMIN FOR A DIVERSITY OF DISEASES
Jaiswal, H., Panda, P. D., & Bharatia, R. (2023) · International Journal of Pharma Professional’s Research (IJPPR) · doi:10.48165/ijppronline.2023.14106
Assessing the antitumor effects of metformin on ovarian clear cell carcinoma
Takemori, S., Morisada, T., Osaka, M., Watanabe, M., Tajima, A., Tanigaki, S., & Kobayashi, Y. (2024) · Human Cell · doi:10.1007/s13577-024-01116-4
Sugiyama, T., Furuno, T., Ichinose, Y., Iwagami, M., Ihana‐Sugiyama, N., Imai, K., Kakuwa, T., Rikitake, R., Ohsugi, M., Higashi, T., et al. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14281 · Cited by 1
Getu, M. A., Zhang, X., Wang, J., Xu, K., Ying, Y., Ma, L., & Gong, P. (2025) · Current Cancer Drug Targets · doi:10.2174/0115680096345507241030224210
Lawrence, W. (2020) · Scholars Archive - University at Albany (University at Albany, State University of New York) · doi:10.54014/76w3-wfa9
Bilder, G. E., & Brown-O’Hara, P. (2025) · Springer eBooks · doi:10.1007/978-3-031-84831-5_10
A Review on the Association Between Metformin Use and Different Types of Anemia
Garmei, M., & Shams, F. (2025) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-025-02025-9
Epidemiology, Screening, and Clinical Staging
Joffe, B. I., Haas, C., & McKiernan, J. M. (2025) · Springer eBooks · doi:10.1007/978-3-031-97599-8_1
Metformin in the Management of Type 2 Diabetes Mellitus: Past, Present, and Future
Kandalkar, N. B., Jayashree.R, P., Rohile, P. V., R., D., & Waidya, K. P. (2025) · International Journal of Advanced Research in Science Communication and Technology · doi:10.48175/ijarsct-29726
Duran, G. A., Kiraz, Y., & Baykara, D. (2025) · Discover Oncology · doi:10.1007/s12672-025-03903-3
Huang, R., Dalton, J., Eichbaum, Y. K., Heard, J. C., Ezeonu, T., Fras, S. I., Garcia, A. G., Oris, R. J., Baidya, J., Narayanan, R., et al. (2025) · Spine · doi:10.1097/brs.0000000000005586
Bellerba, F., Chatziioannou, A. C., Jasbi, P., Robinot, N. R., Keski‐Rahkonen, P., Trolat, A., Vozar, B., Hartman, S. J., Scalbert, A., Bonanni, B., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26558165
Self-citationBellerba, F., Chatziioannou, A. C., Jasbi, P., Robinot, N. R., Keski‐Rahkonen, P., Trolat, A., Vozar, B., Hartman, S. J., Scalbert, A., Bonanni, B., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26558153
Self-citationBellerba, F., Chatziioannou, A. C., Jasbi, P., Robinot, N. R., Keski‐Rahkonen, P., Trolat, A., Vozar, B., Hartman, S. J., Scalbert, A., Bonanni, B., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26558150
Self-citationBellerba, F., Chatziioannou, A. C., Jasbi, P., Robinot, N. R., Keski‐Rahkonen, P., Trolat, A., Vozar, B., Hartman, S. J., Scalbert, A., Bonanni, B., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26558147
Self-citationBellerba, F., Chatziioannou, A. C., Jasbi, P., Robinot, N. R., Keski‐Rahkonen, P., Trolat, A., Vozar, B., Hartman, S. J., Scalbert, A., Bonanni, B., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26558162
Self-citationBellerba, F., Chatziioannou, A. C., Jasbi, P., Robinot, N. R., Keski‐Rahkonen, P., Trolat, A., Vozar, B., Hartman, S. J., Scalbert, A., Bonanni, B., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26558156
Self-citationFontvieille, E., Viallon, V., Recalde, M., Córdova, R., Jansana, A., Peruchet‐Noray, L., Lennon, H., Heath, A. K., Aune, D., Christakoudi, S., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24628106
Bellerba, F., Chatziioannou, A. C., Jasbi, P., Robinot, N. R., Keski‐Rahkonen, P., Trolat, A., Vozar, B., Hartman, S. J., Scalbert, A., Bonanni, B., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26558144
Self-citationBellerba, F., Chatziioannou, A. C., Jasbi, P., Robinot, N. R., Keski‐Rahkonen, P., Trolat, A., Vozar, B., Hartman, S. J., Scalbert, A., Bonanni, B., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26558159
Self-citationBellerba, F., Chatziioannou, A. C., Jasbi, P., Robinot, N. R., Keski‐Rahkonen, P., Trolat, A., Vozar, B., Hartman, S. J., Scalbert, A., Bonanni, B., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26558141
Self-citationMetabolic sabotage: The insulin–cancer conspiracy
Jalal, M. J. A. (2025) · The Journal of Clinical and Scientific Research · doi:10.4103/jcsr.jcsr_90_25
Courtois, S. (2017) · theses.fr (ABES) · doi:10.70675/9cea7a12z80a2z4c42za889z55d1acdfaf97 · Cited by 1
Ariey-Bonnet, J. (2020) · theses.fr (ABES) · doi:10.70675/63ceaea1ze673z40c3z9960zed4c40d88ea9
L'impact de l'adiposité et des maladies cardiométaboliques sur l'incidence et la survie du cancer
Fontvieille, E. (2024) · theses.fr (ABES) · doi:10.70675/9e8c93c3z732fz4707zb3d9z03df95400733
Metformin enhances TRAIL-mediated antitumor activity of liver natural killer cells in mice
Bekki, T., Ohira, M., Imaoka, Y., Imaoka, K., Niitsu, H., Tanaka, Y., Kobayashi, T., & Ohdan, H. (2026) · Scientific Reports · doi:10.1038/s41598-026-45613-y
Özer, M., & Brown, T. J. (2026) · JCO Oncology Practice · doi:10.1200/op-26-00192
Mavros, M. N., Ladak, F., Chan, K., Nguyen, L., Coburn, N. G., & Raphael, M. J. (2026) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359261449094
Abdulhassn, M. L. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-12207-w
НЕЙРОПРОТЕКТОРНЫЕ ФУНКЦИИ МЕТФОРМИНА (ОБЗОР ЛИТЕРАТУРЫ)
Гридасова, Е. И., Плешкова, В. С., Чичкан, А. С., & Смирнова, П. Н. (2026) · Military and tactical medicine Emergency medicine · doi:10.55359/2782-3296.2026.81.44.009
Wespiser, M., Rochefort, P., Gauduchon, T., Coste, C., Caux, C., Ray-Coquard, I. L., Pérol, M., Blay, J., & Heudel, P. (2026) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2026.103200
Mukherjee, A. G., Bharti, A. K., Mathew, D. M., Gopalakrishnan, A. V., & Nishu, S. (2026) · Mammalian Genome · doi:10.1007/s00335-026-10274-9
Saddiq, B. W. B., Morad, A. S., Khan, T. N., Alshowaikhat, J. J., Alsharari, J. N., Bajri, R. O., AlZayer, M. J., Mouazen, S. M., Abutaleb, M. A., Radi, S., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1888506
Antidiabetic drug exposure and risk of bladder cancer: A systematic review and meta-analysis
MATHEZ, W., Vincentelli, A., Chaoui, I., Bruyère, F., & Bourgi, A. (2026) · Urologia Journal · doi:10.1177/03915603261486088
Tseng, Y., Chen, K.-T., Lee, P.-C., Liang-yi, W., Lin, W.-S., Tseng, Y.-H., & Li, C. (2026) · Journal of Nutrition · doi:10.1016/j.tjnut.2026.101855
Biases affecting signal detection and real-world analyses
Antonazzo, I. C., & Ferrara, P. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-26588-4.00007-3
Metadata
- Authors
- Gandini, S., Puntoni, M., Heckman-Stoddard, B. M., Dunn, B. K., Ford, L., DeCensi, A., & Szabo, E.
- Affiliations
- European Institute of Oncology (IT)
- Ente Ospedaliero Ospedali Galliera (IT)
- 3Breast and Gynecologic Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland.
- National Institutes of Health (US)
- National Cancer Institute (US)
- Corresponding author
- Szabo, Eva
- Venue
- Cancer Prevention Research
- Published
- 2014-09-01
- Volume
- 7
- Issue
- 9
- Pages
- 867-885
- ISSN
- 1940-6207 (ISSN-L)
- 1940-6215
- PMC
- PMC4154969
- OpenAlex
- W1976655891
- Cited by
- 457
- References
- 115
- Citations by year
- 2026: 18 · 2025: 29 · 2024: 34 · 2023: 37 · 2022: 47 · 2021: 43 · 2020: 40 · 2019: 43 · 2018: 43 · 2017: 41 · 2016: 43 · 2015: 28 · 2014: 10
- FWCI
- 3.83
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Prevention Research (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (Z99 CA999999)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Oncology › Cancer Risks and Factors
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Nutritional Studies and Diet
- Keywords
- metformin, cancer incidence, cancer mortality, diabetes mellitus, body mass index, confounding, antidiabetic drugs, chemoprevention
- MeSH terms
- Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Metformin, Neoplasms, Risk
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
